188577-68-6Relevant articles and documents
Identification of azabenzimidazoles as potent JAK1 selective inhibitors
Vasbinder, Melissa M.,Alimzhanov, Marat,Augustin, Martin,Bebernitz, Geraldine,Bell, Kirsten,Chuaqui, Claudio,Deegan, Tracy,Ferguson, Andrew D.,Goodwin, Kelly,Huszar, Dennis,Kawatkar, Aarti,Kawatkar, Sameer,Read, Jon,Shi, Jie,Steinbacher, Stefan,Steuber, Holger,Su, Qibin,Toader, Dorin,Wang, Haixia,Woessner, Richard,Wu, Allan,Ye, Minwei,Zinda, Michael
, p. 60 - 67 (2016)
We have identified a class of azabenzimidazoles as potent and selective JAK1 inhibitors. Investigations into the SAR are presented along with the structural features required to achieve selectivity for JAK1 versus other JAK family members. An example from
IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2
-
Page/Page column 132-134, (2021/05/07)
The present application provides improved compositions, methods, kits and dosing regimens for the use of heterocyclic compounds and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, or stereoisomers thereof. These compositions, methods, kit
HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
-
Paragraph 0558-0559, (2017/01/02)
The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a
